Commodity | Reporter | Partner | Trade flow | Indicator | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
3002. Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc | USA | World | Exports | Value (US$) | 10,541,422,754.00 | 11,658,757,692.00 | 14,827,061,227.00 | 17,669,425,339.00 | 19,093,776,468.00 | 20,315,258,267.00 | 23,162,254,940.00 | 25,863,963,793.00 | 26,090,950,690.00 | 43,858,410,440.00 | 43,182,191,316.00 | 49,889,566,439.00 |
Value Growth, YoY (%) | 6.73 | 10.59 | 27.17 | 19.17 | 8.06 | 6.39 | 14.01 | 11.66 | 0.87 | 68.09 | -1.54 | 15.53 | ||||
Imports | Value (US$) | 11,241,412,296.00 | 10,908,524,465.00 | 13,462,960,602.00 | 17,074,222,518.00 | 20,157,949,082.00 | 26,372,010,580.00 | 37,051,743,723.00 | 42,897,133,393.00 | 51,376,632,958.00 | 58,237,948,844.00 | 64,786,027,686.00 | 81,954,945,154.00 | |||
Value Growth, YoY (%) | -2.51 | -2.96 | 23.41 | 26.82 | 18.06 | 30.82 | 40.49 | 15.77 | 19.76 | 13.35 | 11.24 | 26.50 |
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from USA totalled $ 49 billion in 2023. Sales of commodity group 3002 from USA went up by 15.5% compared to 2022: exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 6.7 billion (cumulative exports of commodity group 3002 from USA amounted $43 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 2.47% of total exports from USA (cumulative merchandise exports from USA totalled $ 2.01 trillion in 2023). The share of commodity group 3002 in total exports from USA increased by 0.377 p.p. compared to 2022 (it was 2.09% in 2022 and cumulative exports from USA were equal to $ 2.06 trillion).
Exports of commodity group 3002 amounted to 55% of total sales of group "" from USA in 2023 (the value of exports of commodity group from USA amounted to $90 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from USA increased by 3.52 p.p. compared to 2022 (it was 51% in 2022, and exports of commodity group from USA were $83 billion).
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from USA in 2023:
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to USA totalled $ 81 billion in 2023. Sales of commodity group 3002 to USA went up by 26% compared to 2022: imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 17.1 billion (the value of imports of commodity group 3002 to USA was equal to $64 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 2.58% of total import flow to USA (in 2023, total imports to USA amounted to $ 3.16 trillion). The share of commodity group 3002 in total imports to USA increased by 0.665 p.p. compared to 2022 (it was 1.92% in 2022 and cumulative imports to USA were equal to $ 3.37 trillion).
Imports of commodity group 3002 reached 46% of total imports of group "" to USA in 2023 (imports of commodity group to USA totalled $177 billion in 2023). The share of purchases of commodity group 3002 in total imports of commodity group to USA increased by 6.81 p.p. compared to 2022 (it was 39% in 2022, and imports of commodity group to USA accounted for $164 billion).
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of USA in 2023: